Professional Documents
Culture Documents
,N% Correspondence
1)N% m.branco@qmul.ac.uk (M.R.B.),
&RPSOH[ S S maburguillos@us.es (M.A.B.)
S In Brief
S
Microglia play a key role in
neuroinflammation and
7HW
neurodegeneration in different
neurodegenerative diseases, but little is
7(7 known about the epigenetic modifying
*OXFRVH 7\SH,,)1
enzymes regulating their inflammatory
0HWDEROLVP 5HVSRQVH response. Carrillo-Jimenez et al. identify
TET2 as a major regulator of the microglia
,QÀDPPDWRU\ proinflammatory response and suggest
5HVSRQVH that, by targeting this protein, microglial
activation could be impaired.
Highlights
d TET2 is upregulated in microglia cells upon various
inflammatory stimuli
Article
SUMMARY INTRODUCTION
Epigenomic mechanisms regulate distinct aspects Microglia, the resident immune cells in the CNS, are key players
of the inflammatory response in immune cells. in maintaining homeostasis in the brain. Microglia play a wide va-
Despite the central role for microglia in neuroin- riety of roles under physiological and pathological conditions. In
flammation and neurodegeneration, little is known the healthy brain, microglia are responsible for neuronal activity-
about their epigenomic regulation of the inflamma- dependent synapse pruning during postnatal development
(Schafer et al., 2012; Wu et al., 2015). Upon neuronal injury or
tory response. Here, we show that Ten-eleven
infection, microglia become rapid responders that initiate an
translocation 2 (TET2) methylcytosine dioxygenase
innate inflammatory response (Hanisch and Kettenmann,
expression is increased in microglia upon stimula- 2007). If the inflammatory response is exaggerated or chronic,
tion with various inflammogens through a NF-kB- it becomes detrimental for the surrounding neuronal population,
dependent pathway. We found that TET2 regulates as in Parkinson’s disease (PD) and Alzheimer’s diseases (AD)
early gene transcriptional changes, leading to (Burguillos et al., 2011; Perry and Holmes, 2014; Abeliovich
early metabolic alterations, as well as a later and Gitler, 2016; Ransohoff, 2016), as well as ischemic stroke
inflammatory response independently of its enzy- (Lambertsen et al., 2012; Burguillos et al., 2015).
matic activity. We further show that TET2 regulates In PD or AD, only a minor subset of patients carry genetic mu-
the proinflammatory response in microglia of tations contributing to disease development (Pickrell and Youle,
mice intraperitoneally injected with LPS. We 2015; Abeliovich and Gitler, 2016; Van Cauwenberghe et al.,
2016). Most cases appear to be a combination of genetic predis-
observed that microglia associated with amyloid
position and exposure to environmental risk factors. The identi-
b plaques expressed TET2 in brain tissue from in- fication of mutations in innate immunity-related genes that
dividuals with Alzheimer’s disease (AD) and in confer higher risk for developing neurodegenerative diseases
5xFAD mice. Collectively, our findings show supports the idea of microglia playing a key role in driving dis-
that TET2 plays an important role in the microglial ease pathogenesis (Malik et al., 2015). Hence, epigenetic mech-
inflammatory response and suggest TET2 as a po- anisms are prime candidates for mediating environmentally
tential target to combat neurodegenerative brain driven alterations to immune homeostasis. Indeed, the contribu-
disorders. tion of epigenetic modifications in PD (Park et al., 2016; Wu€ llner
Cell Reports 29, 697–713, October 15, 2019 ª 2019 The Author(s). 697
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
et al., 2016) and AD (Phipps et al., 2016; Watson et al., 2016), has mild but significant upregulation of TET2 in human microglia cells
been addressed in a number of studies. However, despite the (CHME3 human microglia cell line) (Figure 1E). We further
key role of microglia in the neuroinflammatory response in those validated our observations by analyzing RNA sequencing
neurodegenerative diseases, little is known about the epigenetic (RNA-seq) data from postnatal primary microglia cell culture ex-
regulation of the inflammatory response in these cells. periments (Janova et al., 2016), which showed that Tet2 expres-
Major epigenetic mechanisms include post-translational sion was increased both at low and high levels of LPS treatment,
modification of histones, DNA methylation at CpG dinucleotides, as well as after treatment with fibronectin, which also promotes
and regulation by non-coding RNAs (Bonasio et al., 2010). Inter- inflammation (Figure S1A). Fibronectin-mediated regulation of
estingly, the age-dependent increase in microglial IL-1b levels is Tet2 suggests that Tet2 upregulation might not only be driven
associated with DNA hypomethylation within the IL-1b promoter by TLR-4 activation. For this reason, we challenged our BV2 cells
(Matt et al., 2016), which is seemingly driven by the age-depen- with lipoteichoic acid (LTA), a known TLR-2 ligand, and observed
dent loss of SIRT1 (a NAD-dependent deacetylase) (Cho et al., a similar pattern in the expression of Tet2 and Tet3 to that seen in
2015). DNA methylation could therefore play key roles in regu- LPS-treated cells (Figures S1B and S1C). These data show that
lating the inflammatory state in microglia. Importantly, DNA multiple TLR agonists drive Tet2 upregulation in microglia from
methylation can be removed by the action of Ten-eleven translo- different species.
cation (TET) enzymes, which are dioxygenases that catalyze the
oxidation of 5-methylcytosine (5mC) into 5-hydroxymethylcyto- NF-kB p65 Mediates LPS-Induced Tet2 Expression
sine (5hmC) and other oxidative derivatives (Branco et al., We then sought to investigate the mechanisms responsible for
2011). Recently, TETs have been shown to play various roles in the transcriptional regulation of Tet2 upon TLR-4 activation.
the physiology of immune cells, including thymocytes (Tsagara- We first took advantage of published chromatin immunopre-
tou et al., 2017), T helper cells (Ichiyama et al., 2015), dendritic cipitation sequencing (ChIP-seq) data on the TLR-4-induced
cells (Zhang et al., 2015), and bone marrow-derived macro- ‘‘enhancer landscape‘‘ in macrophages (Kaikkonen et al.,
phages (Zhang et al., 2015; Cull et al., 2017). 2013). We used these data as a model for TLR-4-induced reg-
Here, we investigated the role of TET enzymes in the inflam- ulatory events that may also be occurring in microglia cells.
matory response in microglia cells upon Toll-like receptor 4 We mapped data for the activating histone mark H3K27ac,
(TLR-4) activation. We found that TET2 regulates both early tran- as well as various transcription factors, and visually inspected
scription (after only a few hours) of genes affecting several the promoter and upstream regions of Tet2 (profiles in Fig-
pathways (including control of the immune response and cell ure 2A and Figure S2A). In untreated macrophages,
cycle) and the late inflammatory response. We confirmed in vivo H3K27ac was enriched both at the promoter region of Tet2
that TET2 regulates the proinflammatory response in microglia and a region lying 40 kb upstream, thus constituting a putative
cells. Furthermore, we show that TET2 is expressed in distal enhancer element (Figure 2A). Notably, the levels of
microglia close to amyloid b (Ab) plaques in both human AD sub- H3K27ac increased in the upstream region (E1 and E2) after
jects and in 5xFAD mice. All these results highlight the potential 1 h treatment with Kdo2-lipid A (KLA) (a TLR-4 agonist), and
of TET2 as a novel drug target for neurodegenerative diseases, this was concomitant with the recruitment of p65 to both the
including AD. promoter and upstream regions upon KLA treatment (Fig-
ure 2C). In contrast, the binding of CEBPA and PU.1 was
RESULTS largely unaffected by KLA treatment (Figure S2A), suggesting
that p65 is a major driver of TLR-4-dependent activation of
TLR Activation in Microglia Induces Upregulation of Tet2 Tet2. To test whether similar patterns can be observed in
Expression BV2 cells, we performed ChIP followed by qPCR analysis at
To assess the effect of TLR-4 activation on the expression of TET the promoter and upstream regions of Tet2. In concordance
enzymes in microglia, we treated the murine BV2 microglial cell with the results obtained from bone marrow-derived macro-
line with LPS. We found that LPS (1 mg/mL) induced both an early phages (Figure 2A), BV2 cells are enriched for H3K27ac at
2 h (Figure 1A) and sustained 24 h (Figure 1B) upregulation of the Tet2 promoter and at the putative regulatory region up-
Tet2 expression. However, the expression of the other two mem- stream of Tet2 (Figure 2B). Interestingly, H3K27ac levels spe-
bers of the TET family (TET1 and TET3) either did not vary upon cifically increased in the upstream region upon LPS treatment
LPS treatment (Tet3; Figure 1A) or was not detectable (Tet1; not (Figure 2B). Moreover, we detected enrichment for H3K4me1,
shown) before or after LPS treatment. In concordance with the a histone mark associated with both poised and active
RNA data, we detected an increase of TET2 expression at the enhancer elements, providing support for the upstream region
protein level 6 h after LPS treatment (Figure 1C). Interestingly, being an enhancer element that becomes active upon TLR-4
a lower dose of LPS (0.1 mg/mL) also induced Tet2 expression activation (Creyghton et al., 2010). We then analyzed p65
as early as 2 h after treatment (Figure 1D). To rule out the possi- enrichment in the promoter and enhancer regions of Tet2
bility that LPS-induced TET2 expression might be due to the upon LPS treatment in BV2 cells and observed a clear in-
transformed origin of our murine microglia cell line (Butovsky crease in p65 binding at the enhancer region, whereas LPS
et al., 2014), we analyzed the expression of Tet2 in primary adult more subtly modulated the binding of p65 at the promoter re-
and postnatal primary microglia cells from mouse and rat origin gion (Figure 2D). We analyzed the promoter regions of NF-kB
6 h after LPS treatment and obtained similar results to those seen inhibitor alpha (NFkBia) and Il-1b as positive controls for LPS-
in BV2 microglia cells (Figure 1E). Notably, we also observed a dependent p65 binding (Figure S2B). These results suggest a
(Fold of Control)
*
(Fold of Control)
4 4
3 3
n.s
n.s
2 n.s
2
n.s
1 1
0 0
1h 1h 2h 2h 6h 6h 24h
LPS
(1Pg/ml) -+- + -+- + -+- +
LPS
(1Pg/ml) - +
C D E
BV2 cells
BV2 cells CHME3
Primary Primary
Adult Postnatal
TET2 230 kDa 6 * 4 Pglia Pglia
* **
Tet2 gene expression
Tet2 gene expression
n.s
n.s
E-Actin 43 kDa n.s
3 2 *
6h
**
LPS
(Pg/ml)
- +
0.1
+
1.0
1
0 0
2h 6h
LPS
(Pg/ml) -+++++ LPS
(0.1Pg/ml) -+-+-+
1
01
0
1
0. 5
00
1.
0.
0
se
an
0.
00
at
ou
R
um
0.
M
H
Figure 1. LPS Induces an Early and Sustained Expression of Tet2 in Microglia Cells
(A and B) Tet2 and Tet3 expression in BV2 microglia cells treated with LPS (1 mg/mL) at 1, 2 and 6 h (A) and Tet2 expression after 24 h treatment with LPS
(1 mg/mL) (B).
(C) Representative immunoblot showing increase of TET2 and NOS-2 expression (a positive control of microglia activation) at 6 h after LPS treatment
(0.1 and 1 mg/mL) in BV2 cells.
(D) Tet2 LPS-induced dose-response in BV2 microglial cells at 2 h.
(E) Tet2 gene expression after 6 h LPS (0.1 mg/mL) treatment in human microglial cell line (CHME3), primary adult microglia in mouse, and primary postnatal
microglia culture in rat.
Statistical analysis was performed using one-way ANOVA with Scheffé (A and B) and LSD (D) corrections or two-tailed Student’s t test (E). Data shown are mean ±
SD of three (A, D, and E) and five (B) independent experiments. *p < 0.05 and **p < 0.01.
See also Figure S1.
potential role of p65 inTet2 expression through binding to an To test the functional relevance of increased p65 binding to the
upstream enhancer element, increasing its activity, which is upstream region of Tet2 in regulating Tet2 expression upon LPS
reflected by the higher H3K27ac levels in LPS-treated cells. treatment, we pre-treated BV2 cells for 1 h with wedelolactone,
Enrichment relative to H3
Enrichment relative to H3
n.s.
2 2 2 n.s.
*
n.s.
**
1 n.s. 1 1
n.s.
n.s.
n.s.
0 0 0
H3K4me1
H3K4me1
H3K4me1
H3K4me1
H3K4me1
H3K27ac
H3K27ac
H3K27ac
H3K27ac
H3K27ac
P1 P2 M E1 E2
C D-NF-NB p65 ChIP (generated from Kaikkonen et al.,)
Tet2
2000 p65 Ctrl
0
P1 P2 M E1 E2
2000 p65 KLA
0
P1 P2 M E1 E2
D BV2 Mock
BV2 BV2
1.0 1.0 Mock 1.0 Mock
NF-NB p65 NF-NB p65 NF-NB p65
0.8 0.8 0.8
*
** *
% of Input
% of Input
n.s.
0.4 ** 0.4 n.s. 0.4
**
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
LPS
Untreated
LPS
Untreated
LPS
Untreated
LPS
Untreated
LPS
P1 P2 M E1 E2
LPS/Control log2
0.030
% 5-hmC/dG
Fold Change
4
6
0.020 n.s
2 *
0.010 0
0 -2
0.000
3h 3h
siControl ++ - - siControl + - + -
siControl ++ - -
siTET2 - - ++ siTET2 - + - +
siTET2 - - ++
LPS LPS
(1Pg/ml)
-+-+ - + - +
(1Pg/ml)
D E
Inflammation
GO Term (in p-value Enrichment
LPS treated cells): Cell Cycle
Ubiqu
s
n
Ret. in pathwa
k
tio
P P/P
ip
DN A repair
Endocytosis
Ad oplasm
cr
End
it
Cell Cycle 1.50E-12 9.75
ns
he
sine
a
Upregulated
sio
Tr
n
DNA replication 1.40E-08 25.64 . ATP-binding
y
cassette
DNA metabolic process 1.90E-07 10.74
Mitotic Cell Cycle 5.40E-07 11.32
G H
0.016 D-TET2 ChIP Mock 0.03 D-TET2 ChIP
IPTET2
0.012
0.02
% of Input
% of Input
0.008
0.01
0.004
0.000
-- ------ -- 0.00
siTET2 LPS
siTET2 LPS
siTET2 LPS
siTET2 LPS
siTET2 LPS
siControl
siControl
siControl
siControl
siControl
siControl LPS
siControl LPS
siControl LPS
siControl LPS
siControl LPS
LPS - + - + - + - + - +
n.s.
NOS-2 n.s.
2 6h 2 2
EActin
n.s.
)
WT/WT
(Fold of siControl LPS)
Cx3cr1
EActin
Gene expression
- + -
(Fold of
*** +
***
***
***
LPS ***
**
**
*
*
1 1 1
flox/flox
C siControl siTET2
***
LPS TET2
**
1
(Fold of siControl LPS)
NOS-2 expression
0 0 0
3h 6h 24h siTET2 LPS 24h
LPS
siTET2 LPS (100ng/ml) ++
0
LPS 6h 24h
++ ++
(1Pg/ml)
(Fold of LPS TET2flox/flox Cx3cr1WT/WT)
Cx3cr1WT/WT)
F G H siControl siTET2
2 Tet2flox/flox
Cx3cr1 WT/WT
2 Tet2
flox/flox
Cx3cr1
WT/WT
***
*
****
TNF-D release into
IL-6 release into
**
40
flox/flox
** * (pMoles/min)
n.s.
the media
the media
1 1 30
(Fold of LPS TET2
ECAR
20
10
0 0 0
3h 24h
LPS 24h 24h LPS
- + - + - + - +
++ LPS (1Pg/ml)
(100ng/ml) (100ng/ml) ++
siControl siTET2
I J siControl siTET2
BV2
n.s. BV2
1000 * 30
*
** * **
n.s.
glucose in the medium
800
(pMoles/min)
20
600
(mmol/l)
OCR
400
10
200
0 0
LPS 3h 24h LPS 3h
- + - + - + - + - + - +
(1Pg/ml) (1Pg/ml)
Figure 5. TET2 Modulates LPS-Induced Changes in Cellular Metabolism and Inflammatory Response in Microglia Cells
(A) Graph showing the gene expression of Il-1b, Nos-2, and Il-6 in LPS-treated BV2 cells with or without TET2 gene knockdown at different time points.
(B) and C) Representative immunoblot (B) and quantification (C) of NOS-2 protein at 6 and 24 h LPS treatment in BV2 cells transfected with siRNA control and
siRNA Tet2.
(D) Quantification of IL-6 release into the media upon LPS treatment at different times (3, 6 and 24 h).
(E) Analysis of Nos-2 gene expression in primary microglia cells after 24 h treatment with LPS.
(F and G) Histograms showing the effect of TET2 gene knockdown over IL-6 (F) and TNF-a (G) in LPS-treated primary microglia cells.
(H–J) Histograms showing the extracellular acidification rate (ECAR) (H), oxygen consumption rate (OCR) (I), and concentration of glucose (J) in the media in BV2
cells treated at different times with LPS.
Data shown are mean ± SD of five (A) and three (C) independent experiments. Data shown in (D) are mean ± SEM of nine (3 h), six (6 h), and eight (24 h) inde-
pendent experiments. Data shown in (E) are mean ± SD of seven independent experiments. Data shown in (F) and (G) are mean ± SEM of nine (F) and three (G)
independent experiments. Data shown in (H)–(J) are mean ± SD of three independent experiments. Statistical analysis was performed using two-tailed Student’s
t test. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
See also Figure S5.
***
***
+ PBS
*
flox/flox Cre/WT
Tet2 Cx3cr1
**
400.0 n.s. 100 Tet2
flox/flox
Cx3cr1
Cre/WT
+ LPS
**
PBS
% of microglia population
2
Number of Microglia/mm
80
300.0
*** ***
60
Iba-1 Iba-1
***
200.0
***
40
* *
100.0
LPS
20 n.s.
0 0
LPS - + - +
Iba-1 Iba-1
Homeostatic Reactive Macrophage
Nox-2 Cox-2
*
flox/flox
D E F Tet2 Cx3cr1WT/WT
n.s. 330 Tet2
flox/flox
Cx3cr1
Cre/WT
2000 300
)
(Fold of Tet2flox/floxCx3cr1WT/WT)
WT/WT
30 * **
in substantia nigra
Gene expression
Gene expression
n.s.
200
20
1000
100
10
0 0
LPS - - ++ LPS - - ++ 0
LPS - + - +
Iba-1
COX-2
Merge
Figure 6. Abrogation of Tet2 in Microglia Cells Decreases the LPS-Induced Immune Response In Vivo
(A–C) Iba-1 immunostaining in substantia nigra of Tet2flox/floxCx3cr1 Cre/WT and Tet2flox/floxCx3cr1WT/WT mice treated for 4 days either with LPS or vehicle (PBS)
and sacrificed 24 h later (A) and analysis of microglia cell numbers (B) and activation status on the basis of morphology (C).
(D and E) qRT-PCR analysis of Nox-2 (D) and Cox-2 (E) in Tet2flox/floxCx3cr1 Cre/WT and Tet2flox/floxCx3cr1WT/WT mice treated for 4 days either with LPS or vehicle
(PBS) and sacrificed 24 h later.
(F and G) Quantification of Cox-2 staining (F) in Iba-1-positive cells (G) in the same type of mice.
Data represented as mean ± SEM. The results correspond to three independent experiments in (B) and (C). In (D) and (E), the number of independent experiments
is equal to three for Tet2flox/floxCx3cr1WT/WT + LPS and seven for Tet2flox/floxCx3cr1Cre/WT + LPS. In (G), all treatments are three independent experiments except
Tet2flox/floxCx3cr1Cre/WT + LPS, which is four independent experiments. Statistical analysis was performed using one-way ANOVA with a Student-Newman-Keuls
post hoc test (C and G) or two-tailed Student’s t test (D and E). *p < 0.05, **p < 0.01, ***p < 0.01. Scale bar in (A) is 10 mm and in (G) is 20 mm.
See also Figure S6.
particles/Iba-1 area
0.3
Ratio TET2 +
Hoechst Iba-1 E-Amyloid 0.2
0.1
Range indicator (TET2) TET2 10 Pm
0 Inside Outside
plaques plaques
D ns ns E
25000 ****
IBA1-positive cell in
20000
TET2 CTCF
5000
-5000
Subject 1 Subject 2 Subject 3
ACKNOWLEDGMENTS REFERENCES
We would like to thank to Dr. de la Rica (Queen Mary University of London) for Abeliovich, A., and Gitler, A.D. (2016). Defects in trafficking bridge Parkinson’s
technical support and Dr. Hornedo-Ortega (University of Seville) for providing disease pathology and genetics. Nature 539, 207–216.
us with the a-synuclein. A.C.-J. is supported by a pre-doctoral fellowship from Alhadidi, Q., and Shah, Z.A. (2018). Cofilin mediates LPS-induced microglial
the Spanish Ministerio de Educación, Cultura y Deporte. Ö.D. has received cell activation and associated neurotoxicity through activation of NF-kB and
funding from the People Programme (Marie Curie Actions) of the European JAK-STAT pathway. Mol. Neurobiol. 55, 1676–1691.
Union’s Seventh Framework Programme (FP7/2007-2013) under REA grant
Bal-Price, A., and Brown, G.C. (2001). Inflammatory neurodegeneration medi-
agreement 608765. M.V.N.-C. received a Children with Cancer UK fellowship
ated by nitric oxide from activated glia-inhibiting neuronal respiration, causing
(14-178). This work was supported by grants from Blizard Research Theme
glutamate release and excitotoxicity. J. Neurosci. 21, 6480–6491.
grants Queen Mary University of London; Blizard Institute; Spanish Ministerio
Bal-Price, A., Matthias, A., and Brown, G.C. (2002). Stimulation of the NADPH
de Ciencia, Innovación y Universidades/FEDER/UE RTI2018-098645-B-100;
oxidase in activated rat microglia removes nitric oxide but induces peroxyni-
Swedish Research Council; ERA-NET TracInflam; Swedish Brain Foundation;
trite production. J. Neurochem. 80, 73–80.
and Karolinska Institutet Foundations. M.R.B. is a Sir Henry Dale Fellow
(101225/Z/13/Z), jointly funded by the Wellcome Trust and the Royal Society. Benusa, S.D., George, N.M., Sword, B.A., DeVries, G.H., and Dupree, J.L.
M.A.B. has been funded by the Barts Charity Centre for Trauma Sciences (2017). Acute neuroinflammation induces AIS structural plasticity in a NOX2-
(C4TS), the Wellcome Trust Institutional Strategic Support Fund (ISSF), and dependent manner. J. Neuroinflammation 14, 116.
the Spanish Ministry of Economy and Competitivity (Programa Ramón y Cajal: Bodea, L.G., Wang, Y., Linnartz-Gerlach, B., Kopatz, J., Sinkkonen, L., Mus-
RYC-2017-21804). grove, R., Kaoma, T., Muller, A., Vallar, L., Di Monte, D.A., et al. (2014). Neuro-
degeneration by activation of the microglial complement-phagosome
AUTHOR CONTRIBUTIONS pathway. J. Neurosci. 34, 8546–8556.
Bonasio, R., Tu, S., and Reinberg, D. (2010). Molecular signals of epigenetic
M.A.B. and M.R.B. designed the study. A.C.-J., J.L.V., I.G.-D., J.G.-R., states. Science 330, 612–616.
J.C.F.-M., and R.R. performed all the experiments with the Tet2flox/flox;
Booth, M.J., Branco, M.R., Ficz, G., Oxley, D., Krueger, F., Reik, W., and Ba-
Cx3Cr1Cre/wt and Tet2flox/flox; Cx3Cr1wt/wt mice. Ö.D. performed the ChIP anal-
lasubramanian, S. (2012). Quantitative sequencing of 5-methylcytosine and
ysis for NF-kB p65 and H3K27ac and H3K4me1 antibodies. Ö.D. and M.A.B.
5-hydroxymethylcytosine at single-base resolution. Science 336, 934–937.
performed the ChIP analysis for TET2 antibody. M.V.N.-C. determined the
ECAR and OCR index and glucose consumption in BV2 cells. K.B.-S. per- Boza-Serrano, A., Reyes, J.F., Rey, N.L., Leffler, H., Bousset, L., Nilsson, U.,
formed the oxBS sequencing experiments. V.S. and X.S. performed the stain- Brundin, P., Venero, J.L., Burguillos, M.A., and Deierborg, T. (2014). The role
ing and analysis of TET2 expression in AD subjects. R.A. and P.H. performed of galectin-3 in a-synuclein-induced microglial activation. Acta Neuropathol.
the mass spectrometry analysis for global levels of 5mC and 5hmC. A.V. and Commun. 2, 156.
G.C.B. performed the analysis of TET2 in rat postnatal primary microglia. Branco, M.R., Ficz, G., and Reik, W. (2011). Uncovering the role of 5-hydrox-
P.K.Y. performed the analysis of TET2 in mouse adult primary microglia. ymethylcytosine in the epigenome. Nat. Rev. Genet. 13, 7–13.
M.C. performed the analysis of TET2 in the human microglia cell line Burguillos, M.A., Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-
CHME3. R.R. performed the analysis of TET2 in the 5xFAD mice brain tissue Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J.L., and Joseph,
and in Tet2flox/flox; Cx3Cr1WT/WT and Tet2flox/flox;Cx3Cr1Cre/WT injected with B. (2011). Caspase signalling controls microglia activation and neurotoxicity.
LPS. R.R. also performed the confocal analysis of microglia morphology and Nature 472, 319–324.
COX-2. A.M.S.-E. analyzed TET2/3 expression in BV2 cells after LTA treat-
Burguillos, M.A., Svensson, M., Schulte, T., Boza-Serrano, A., Garcia-Quinta-
ment. K.T. and A.M.E.-O. and P.S.-H. analyzed the expression levels of
nilla, A., Kavanagh, E., Santiago, M., Viceconte, N., Oliva-Martin, M.J., Osman,
TET2 in BV2 upon a-synuclein and b-oligomer treatments. E.R. provided the
A.M., et al. (2015). Microglia-secreted galectin-3 acts as a toll-like receptor 4
AD subject tissue. I.G.-D., J.G.-R., J.C.F.-M. performed the isolation of RNA
ligand and contributes to microglial activation. Cell Rep. 10, 1626–1638.
from SN from mice injected with LPS and performed the qPCR analysis for
Burm, S.M., Zuiderwijk-Sick, E.A., ’t Jong, A.E., van der Putten, C., Veth, J.,
the different cytokines and COX2 and NOX2. M.R.B. performed the RNA-
Kondova, I., and Bajramovic, J.J. (2015). Inflammasome-induced IL-1b secre-
seq experiments and analyzed the data. M.A.B. performed the qPCR analysis
tion in microglia is characterized by delayed kinetics and is only partially
and immunoblots for the study of the inflammatory response in BV2 cells.
dependent on inflammatory caspases. J. Neurosci. 35, 678–687.
J.L.V. and B.J. were involved in the study design. M.A.B. and M.R.B. wrote
the manuscript with all the authors. All authors discussed the results and com- Butovsky, O., Jedrychowski, M.P., Moore, C.S., Cialic, R., Lanser, A.J., Ga-
mented on or edited the manuscript. briely, G., Koeglsperger, T., Dake, B., Wu, P.M., Doykan, C.E., et al. (2014).
Identification of a unique TGF-b-dependent molecular and functional signature
DECLARATION OF INTERESTS in microglia. Nat. Neurosci. 17, 131–143.
Chen, Z., Jalabi, W., Shpargel, K.B., Farabaugh, K.T., Dutta, R., Yin, X., Kidd,
The authors declare no competing interests. G.J., Bergmann, C.C., Stohlman, S.A., and Trapp, B.D. (2012).
Figure 7. Microglial TET2 Expression in 5xFAD Mice and Alzheimer’s Disease Brain Tissue
(A–D) Colocalization analysis of TET2, Iba-1, and Ab plaques in the hippocampus of 18-month-old 5xFAD mice (A and B) and three AD subjects (C and D).
(E) Details of age, gender, and Braak stage for each AD subject.
Data shown in (B) are mean ± SEM of three independent experiments. Arrowheads indicate microglial cells. In (D), each shape represents intensity from some
single microglia found either in the white matter (black circles) or inside a plaque (red squares). Statistical analysis used for (B) was two-tailed Student’s t test and
for (D) was one-way ANOVA with Sidak’s multiple-comparison test. CTCF, corrected total cell fluorescence. *p < 0.05 and ****p < 0.0001. Scale bar for (A) is 10 mm
and for (C) is 50 mm.
See also Figure S7.
Stifter, S.A., and Feng, C.G. (2015). Interfering with immunity: detrimental role Zarruk, J.G., Greenhalgh, A.D., and David, S. (2018). Microglia and macro-
of type I IFNs during infection. J. Immunol. 194, 2455–2465. phages differ in their inflammatory profile after permanent brain ischemia.
Tannahill, G.M., Curtis, A.M., Adamik, J., Palsson-McDermott, E.M., Exp. Neurol. 301 (Pt B), 120–132.
McGettrick, A.F., Goel, G., Frezza, C., Bernard, N.J., Kelly, B., Foley, N.H., Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang,
et al. (2013). Succinate is an inflammatory signal that induces IL-1b through C., Zhang, X., et al. (2015). Tet2 is required to resolve inflammation by recruit-
HIF-1a. Nature 496, 238–242. ing Hdac2 to specifically repress IL-6. Nature 525, 389–393.
This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to
and will be fulfilled by the Lead Contact, Miguel Angel Burguillos (maburguillos@us.es).
METHOD DETAILS
RNA-seq
mRNA-seq libraries were prepared from 1 mg of total RNA using the Dynabeads mRNA purification kit (ThermoFisher Scientific) and
the low input ScriptSeq Complete Gold Kit (Epicenter). Libraries were sequenced on an Illumina NextSeq 500 with single-end 75 bp
reads. Reads were trimmed using Trim_galore! v0.3.3 and mapped using Tophat v2.0.9 (Trapnell et al., 2009) to the mm9 genome
assembly. Raw read counts for each gene were generated in Seqmonk with the RNA-seq quantitation pipeline. DESeq2 was then
used for differential expression analysis and for generating normalized gene expression values. Gene ontology analysis was per-
formed using the R package topGO.
Immunoblotting
All cell extracts were processed for immunoblotting with a SDS-polyacrylamide gel electrophoresis as described previously (Burguil-
los et al., 2015). Briefly, Laemmli’s loading buffer (100 ml/106 cells) was added to harvested cells and samples were boiled for 3 min.
Thirty ml of protein extracts were resolved on 8, 0r 12% SDS polyacrylamide gel at 150 V and transblotted onto nitrocellulose mem-
branes (0.2 mm) for 2 h at 200 mA. Membranes were blocked overnight in a buffer (50 mM Tris, pH 7.5, 500 mM NaCl) supplemented
by 5% non-fat milk powder and probed with primary antibody for overnight, in blocking solution with 1% Bovine serum albumin, fol-
lowed by the incubation with secondary antibody for 1 h at room temperature. After repeated washing in PBS bands were visualized
by ECL according to the manufacturer’s instruction. A complete list of primary antibodies can be found in the Key resources table.
b-actin antibody (Sigma-Aldrich) was used to verify equal loading of the gel. Secondary horseradish peroxidase-conjugated anti-rab-
bit and anti-mouse antibodies were obtained from Dako.
Cell viability
Cell viability was quantified by CellTiter-Glo Luminescent Cell Viability Assay according to the manufacturer’s instructions.
Detection is based on using the luciferase reaction to measure the amount of ATP from viable cells. The plate used was opaque
to limit interference from external light. The intensity of the emitted light due to the degradation of D-Luciferin and ATP by the enzyme
Luciferase is proportional to the amount of free ATP present at that moment in the cells.
Chromatin Immunoprecipitation
BV2 cells were treated with 1mg/ml of LPS during 6h. For each histone modification ChIP, the cells were washed with PBS and fixed
by 1% formaldehyde for 12 min at RT. For NF-kB ChIP, the cells were first fixed with 2 mM DSG in PBS for 45 min at RT followed by
1% of formaldehyde fixation for 12 min. After stopping the fixation with 0.125 M glycine, the cells were washed with cold PBS and
collected by centrifugation. Subsequently, the cells were washed with wash buffer (10 mM HEPES/KOH at pH 7.9, 85 mM KCl, 1mM
EDTA, 0.5% IGEPAL) once, lysed with lysis buffer (50 mM Tris at pH 7.4, 1% SDS, 0.5% Empigen, 10 mM EDTA, 1mM PMSF) sup-
plemented by protease inhibitors for 30 min on ice and the chromatin was sonicated to an average size of 300-700 bp. For immu-
noprecipitation, the soluble chromatin was diluted ten times in dilution buffer (50 mM Tris at pH 8.0, 0.5% NP-40, 0.2 M NaCl and
0.5 mM EDTA) and incubated with 5 mg of antibodies selective for NF-kB p65, H3K27ac, H3K4me1 or TET2 overnight at 4 C. The
immune complexes were collected with protein G beads for 2 h at 4 C, washed with low salt buffer (50 mM Tris at pH 8.0, 0.1%
SDS, 1% NP-40, 2 mM EDTA, 0.5% Deoxycholate and 0.15 M NaCl), high salt buffer (50 mM Tris at pH 8.0, 0.1% SDS, 1%
NP-40, 2 mM EDTA, 0.5% Deoxycholate and 0.5 M NaCl) and LiCl buffer (50 mM Tris at pH 8.0, 1% NP-40, 2 mM EDTA, 0.5%
Deoxycholate and 0.25 M LiCl), respectively. Immunoprecipitates were eluted in 1% SDS and 0.1 M sodium bicarbonate and the
crosslinks were reversed overnight. After proteinase K digestion, DNA was extracted using GeneJET PCR purification kit. Immuno-
precipitated DNA was analyzed by real time PCR using specific primers
Microglia morphology
The proportion of the different microglial morphology was estimated according with the follow classification (see Figure 6, insets): (1)
Quiescent microglia with small cell bodies, fine cytoplasmic ramifications, and low to moderate Iba1 expression; (2) microglia with
early-stage activation characterized by increased ramification of cytoplasmic processes and cell size, and enhanced Iba1 labeling;
(3) Microglia corresponding to next step of activation is characterized by further thickening of processes and retraction of the thinest
ones, as well as increased cell body size and Iba1 expression; and finally, (3) amoeboid cells, showing complete retraction of
cytoplasmic processes with maintained high levels of Iba1 expression.
Images quantification
The proportion of microglia in the SN in each LPS experiment experimental group was estimated using cell counter plugin included in
Fiji ImageJ (W. Rasband, National Institutes of Health) software. In the SN of the different experimental groups we measured the mean
intensity of the specific fluoresce markers (TET2 and COX-2), in Iba1 positive cells. To do that, we performed mask outlined of Iba1
area using exactly the same value of threshold in each image and then, we measured automatically the mean intensity inside of these
areas using, again, the Fiji software.
The statistical details of experiments, including statistical tests used, number of experiments, and dispersion and precision
measures, can be found in the figure legends. The differences between control and experimental groups were evaluated with either
two-tailed Student’s t test, one way or two-way ANOVA with different corrections depending on the experiment. We used Stat-
graphics Centurion XVII (64-bit) for PC (http://www.statgraphics.com/centurion-xvii) and R software for Mac (https://www.
r-project.org/) for the statistical analyses. p < 0.05 was considered as statistically significant.
The accession number for the RNA-seq data reported in this paper is NCBI GEO: GSE105155.
Supplemental Information
Tet2 expression after different proinflammatory stimuli in primary postnatal murine microglia generated from
the RNAseq data obtained from (Janova et al., 2016) (A). Tet2 (B) and Tet3 (C) gene expression after 1h and 2h
treatment with 50 g/ml lipoteichoic acid (LTA) in BV2 cells. Data are represented as mean ± SD of three
independent experiments (A, B, C), using one-way ANOVA with Scheffe correction (B, C). *P < 0.05
Figure S2 (related to Figure 2): ChIP-seq profile of Tet2 promoter after TLR4 activation.
Analysis of data from the study published in (Kaikkonen et al., 2013), covering the Tet2 promoter and upstream
regions for CEBPA and PU.1 transcription factors in peripheral macrophages treated with KLA (an agonist for
TLR-4) (A). NFBia and Il-1were used as positive controls of genes under p65 transcriptional control upon
LPS treatment in BV2 microglia cells (B). Measurement of LPS-induced Il-1(C) and Tet2 expression (D) with
and without pre-treatment of wedelactone (30 μM) for 1 h. LPS-induced Il-1 was used as a positive control for
a gene regulated through NF-B p65 in BV2 microglia cells. Data represented in B are representative replicate
of two biological replicates. Data represented in B, C and D are represented as mean ± SD from three (C, D)
and four (B) independent experiments. Statistical analysis was performed using two-tailed Students t-test (B-D).
*P < 0.05, ***P < 0.001, ****P < 0.0001
Figure S3 (related to Figure 3): Validation of several targets obtained from the RNAseq. data
Scatter plots comparing our RNA-seq data generated in BV2 cells (Y axis) with the RNA-seq data obtained
from a published study using primary postnatal microglia (Janova et al., 2016) (X axis). The log2 fold-change in
gene expression upon LPS treatment is plotted. Red data points represent genes that are differentially expressed
in BV2 cells when comparing LPS-treated cells with untreated controls (A). Venn diagrams generated from our
RNAseq data in BV2 representing the number of genes affected by LPS treatment and siRNA TET2 treatment.
Validation of the effect of TET2 knockdown on gene expression on selected gene targets obtained in our RNA-
seq (C). Dot plot (D) and bar chart (E) of the analysis of Annexin V/PI staining in BV2 cells transfected with
siControl and siTET2 for 48 hours and treated with LPS (1g/ml) for 3 hours. Analysis of total number of cells
(F) and % of survival (G) in staining in BV2 cells transfected with siControl and siTET2 for 48 hours and
treated with LPS (1g/ml) for 3 hours. Bright field photographs of BV2 cells transfected with siControl and
siTET2 for 48 hours and treated with LPS (1g/ml) for 3 hours (H). Data shown are represented as mean ± SD
from two (G), three (C), four (F) and six (C, E) independent experiments. Two-tailed Student's t-test. *P < 0.05,
**P < 0.01, ***P < 0.001. Scale bar in H is 100 m
Figure S4 (related to Figure 4): Oxidative bisulfite (oxBS) sequencing of different genes affected by LPS
treatment.
Global DNA methylation analysis in transfected microglia (siControl and siTet2) with and without 3h treatment
with LPS (1g/ml). Data shown represent the mean ± s.d from three independent experiments and statistics were
performed using two-tailed Student’s t-test (A). Quantification by oxBS-seq of 5-hmC levels after 3h LPS
treatment of different target genes (blue bars indicate the position of the analysed amplicons) (B-G). TET2 ChIP
of Cxcl10 , Irf1 Cd274, Pfkb3 and Oct4 (used here as a negative control) genes after 3h treatment with LPS
(1g/ml) and including a siRNA Tet2 LPS control (H). Data shown represent the mean of two technical
replicates. Statistics were performed using two-way ANOVA with a Tuckey post-hoc test tacking into account
all CpGs. We include the p value for genes with a statistically significant difference in the graphs (B-G). Data
representative of one technical replicate in H.
Figure S5 (related to Figure 5): Representative example of ECAR and OCR graphs and the effect of 2-
deoxy-D-glucose on the inflammatory response induced by LPS
A schematic diagram depicting the mechanism of how treatment with 4-hydroxitamoxifen promotes the excision
of Tet2 allele 3 by using the Cre-lox system (A). Gel electrophoresis of Biopsy (B) and primary microglia DNA
(C) from Tet2flox/flox and Tet2flox/floxCx3cr1Cre/WT mice (B). Quantification of Tet2 expression using primers that
recognize exon 3 in primary microglia from Tet2flox/floxCx3cr1Cre/WT and Tet2flox/floxCx3cr1WT/WT mice with and
without 24h LPS treatment (100 ng/ml) (C). Example of line charts for ECAR and OCR generated with
Seahorse technology in siRNA control and siRNA Tet2 BV2 microglia cells treated with LPS for 3h (D and E).
NOS-2 expression in BV2 cells treated with different doses of 2-deoxy-D-glucose and LPS for 6 h (F and G).
Data represented in C and G are shown as mean ± SD of four (C and G) and five (C) independent experiments.
Statistics were performed using one-way ANOVA with LSD correction in G. *P < 0.05, **P < 0.01
Figure S6 (related to Figure 6): Effect of intraperitoneal LPS in Tet2flox/flox and Tet2flox/floxCx3cr1Cre/WT mice
A schematic diagram depicting the number and time of intraperitoneal LPS injections and the day that the mice
were sacrificed and their brain tissue analyzed (A). Analysis in vivo of TET2 expression in microglia cells
treated only with PBS intraperitoneal injections (following the same pattern of injections as with LPS
intraperitoneal injections) (B and C). RT-qPCR for Il-1, Nos-2, Tnf-expression in substantia nigra of
Tet2flox/floxCx3cr1Cre/WT and Tet2flox/floxCx3cr1WT/WT treated with LPS or PBS. Data shown as mean ± SEM in C
and D. The number or independent experiments is three in C and in D, four in Tet2flox/floxCx3cr1Cre/WT and
Tet2flox/floxCx3cr1WT/WT PBS treated, three Tet2flox/floxCx3cr1WT/WT LPS treated and five Tet2flox/floxCx3cr1Cre/WT
LPS treated, independent experiments. Scale bar in B is 10 m. *P < 0.05
Figure S7 (related to Figure 7): Microglial TET2 expression upon -synuclein and A-oligomer treatment
and in 5xFAD mice and AD patients.
Tet2 expression in BV2 microglial cells after 6 h treatment with -synuclein fibrils (5µM) and A-oligomers (2
µM). (A). Low magnification of colocalization pictures from Figure 7A (dotted rectangle) in hippocampus of
Iba-1, TET2 and -amyloid in 18 month-old 5xFAD brain sections (B). Data represented as mean ± SD of four
independent experiments for -synuclein fibrils and four independent experiments for A-oligomers. Statistical
analysis was performed using one-way ANOVA with Scheffe correction *P < 0.05, **P < 0.01. Scale bar in B
is 50 m
Table S1. Primers sequences for RT-qPCR. Related to Key Resources Table. Source for all the
primers is this paper.
Table S2. Primers sequences for ChIP. Related to Key Resources Table. Source for all the
primers is this paper.
Table S3. Primers sequences for Ox-Bs sequencing. Related to Key Resources Table. Source
for all the primers is this paper.